259 related articles for article (PubMed ID: 29164965)
1. The importance of FLT3 mutational analysis in acute myeloid leukemia.
Patnaik MM
Leuk Lymphoma; 2018 Oct; 59(10):2273-2286. PubMed ID: 29164965
[TBL] [Abstract][Full Text] [Related]
2. Overcoming Resistance to FLT3 Inhibitors in the Treatment of
Lam SSY; Leung AYH
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102366
[TBL] [Abstract][Full Text] [Related]
3. The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia.
Bruzzese A; Vigna E; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Stanzione G; Zimbo A; Lugli E; Neri A; Morabito F; Gentile M
Expert Rev Hematol; 2024 Jun; 17(6):241-253. PubMed ID: 38748404
[TBL] [Abstract][Full Text] [Related]
4. Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
Wang ES; Goldberg AD; Tallman M; Walter RB; Karanes C; Sandhu K; Vigil CE; Collins R; Jain V; Stone RM
J Clin Oncol; 2024 May; 42(15):1776-1787. PubMed ID: 38324741
[TBL] [Abstract][Full Text] [Related]
5. Fms -like tyrosine kinase 3 positive acute myeloid leukemia.
Isidori A; Visani G; Ferrara F
Curr Opin Oncol; 2023 Nov; 35(6):589-593. PubMed ID: 37820093
[TBL] [Abstract][Full Text] [Related]
6. Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors.
Short NJ; Nguyen D; Ravandi F
Blood Cancer J; 2023 Sep; 13(1):142. PubMed ID: 37696819
[TBL] [Abstract][Full Text] [Related]
7. Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML.
Macečková D; Vaňková L; Holubová M; Jindra P; Klieber R; Jandová E; Pitule P
Mol Biol Rep; 2024 Apr; 51(1):521. PubMed ID: 38625438
[TBL] [Abstract][Full Text] [Related]
8. FLT3 inhibitors in acute myeloid leukemia.
Wu M; Li C; Zhu X
J Hematol Oncol; 2018 Dec; 11(1):133. PubMed ID: 30514344
[TBL] [Abstract][Full Text] [Related]
9. MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia.
Morales ML; Arenas A; Ortiz-Ruiz A; Leivas A; Rapado I; Rodríguez-García A; Castro N; Zagorac I; Quintela-Fandino M; Gómez-López G; Gallardo M; Ayala R; Linares M; Martínez-López J
Sci Rep; 2019 Dec; 9(1):18630. PubMed ID: 31819100
[TBL] [Abstract][Full Text] [Related]
10. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Sato T; Yang X; Knapper S; White P; Smith BD; Galkin S; Small D; Burnett A; Levis M
Blood; 2011 Mar; 117(12):3286-93. PubMed ID: 21263155
[TBL] [Abstract][Full Text] [Related]
11. Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia.
Wiesen MHJ; Stemler J; Fietz C; Joisten C; Cornely OA; Verougstraete N; Streichert T; Müller C
Eur J Haematol; 2024 Jun; 112(6):879-888. PubMed ID: 38297484
[TBL] [Abstract][Full Text] [Related]
12. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
Larson RA; Mandrekar SJ; Huebner LJ; Sanford BL; Laumann K; Geyer S; Bloomfield CD; Thiede C; Prior TW; Döhner K; Marcucci G; Voso MT; Klisovic RB; Galinsky I; Wei AH; Sierra J; Sanz MA; Brandwein JM; de Witte T; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Krauter J; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Gathmann I; Döhner H; Stone RM
Leukemia; 2021 Sep; 35(9):2539-2551. PubMed ID: 33654204
[TBL] [Abstract][Full Text] [Related]
13. Day-21 bone marrow findings incorrectly designate residual leukaemia in FLT3-mutated acute myeloid leukaemia treated with intensive induction plus midostaurin: a morphology-focused study.
Tedjaseputra A; Roy S; Htun K; Oh D; McQuilten Z; Yeh P; Bennett A; Low MSY; Chunilal S; Wood EM; Shortt J
Pathology; 2024 Jun; 56(4):548-555. PubMed ID: 38580614
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia.
Lee JS; Wagner CB; Prelewicz S; Kurish HP; Walchack R; Cenin DA; Patel S; Lo M; Schlafer D; Li BKT; Donald Harvey Iii R; Wasef B; Ying J; Kovacsovics T
Haematologica; 2023 Dec; 108(12):3460-3463. PubMed ID: 37345485
[No Abstract] [Full Text] [Related]
15. Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
Dumas PY; Raffoux E; Bérard E; Bertoli S; Hospital MA; Heiblig M; Desbrosses Y; Bonmati C; Pautas C; Lambert J; Orvain C; Banos A; Pasquier F; Peterlin P; Marchand T; Uzunov M; Frayfer J; Turlure P; Cluzeau T; Jourdan E; Himberlin C; Tavernier E; Villate A; Haiat S; Chretien ML; Carre M; Chantepie S; Vaida I; Wemeau M; Chebrek S; Guillerm G; Guièze R; Debarri H; Gehlkopf E; Laribi K; Marcais A; Santagostino A; Béné MC; Mineur A; Pigneux A; Dombret H; Récher C
Leukemia; 2023 Jan; 37(1):91-101. PubMed ID: 36376378
[TBL] [Abstract][Full Text] [Related]
16. Preclinical characterization of danatinib as a novel FLT3 inhibitor with excellent efficacy against resistant acute myeloid leukemia.
Sun SL; Wu JZ; Wang JJ; Zhou H; Zhang CQ; Tong ZJ; Wang YB; Sha JK; Wang QX; Liu JC; Zheng XR; Li QQ; Zhang MY; Yang J; Wei TH; Wang ZX; Yu YC; Ding N; Leng XJ; Xue X; Li HM; Dai WC; Yin XY; Yang Y; Duan JA; Li NG; Shi ZH
Biomed Pharmacother; 2023 Dec; 169():115905. PubMed ID: 38000356
[TBL] [Abstract][Full Text] [Related]
17. FLT3 Mutations in Acute Myeloid Leukemia: Unraveling the Molecular Mechanisms and Implications for Targeted Therapies.
Jalte M; Abbassi M; El Mouhi H; Daha Belghiti H; Ahakoud M; Bekkari H
Cureus; 2023 Sep; 15(9):e45765. PubMed ID: 37872917
[TBL] [Abstract][Full Text] [Related]
18. Metabolomic profile of acute myeloid leukaemia parallels of prognosis and response to therapy.
Bolkun L; Pienkowski T; Sieminska J; Godzien J; Pietrowska K; Kłoczko J; Wierzbowska A; Moniuszko M; Ratajczak M; Kretowski A; Ciborowski M
Sci Rep; 2023 Dec; 13(1):21809. PubMed ID: 38071228
[TBL] [Abstract][Full Text] [Related]
19. Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia.
Medinger M; Lengerke C; Passweg J
Cancer Genomics Proteomics; 2016 09-10; 13(5):317-29. PubMed ID: 27566651
[TBL] [Abstract][Full Text] [Related]
20. A practical algorithm for acute myeloid leukaemia diagnosis following the updated 2022 classifications.
Della Porta MG; Martinelli G; Rambaldi A; Santoro A; Voso MT
Crit Rev Oncol Hematol; 2024 Jun; 198():104358. PubMed ID: 38615870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
